1
|
Kay VR, Rätsep MT, Figueiró-Filho EA, Croy BA. Preeclampsia may influence offspring neuroanatomy and cognitive function: a role for placental growth factor†. Biol Reprod 2020; 101:271-283. [PMID: 31175349 DOI: 10.1093/biolre/ioz095] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 01/30/2019] [Accepted: 06/06/2019] [Indexed: 01/01/2023] Open
Abstract
Preeclampsia (PE) is a common pregnancy complication affecting 3-5% of women. Preeclampsia is diagnosed clinically as new-onset hypertension with associated end organ damage after 20 weeks of gestation. Despite being diagnosed as a maternal syndrome, fetal experience of PE is a developmental insult with lifelong cognitive consequences. These cognitive alterations are associated with distorted neuroanatomy and cerebrovasculature, including a higher risk of stroke. The pathophysiology of a PE pregnancy is complex, with many factors potentially able to affect fetal development. Deficient pro-angiogenic factor expression is one aspect that may impair fetal vascularization, alter brain structure, and affect future cognition. Of the pro-angiogenic growth factors, placental growth factor (PGF) is strongly linked to PE. Concentrations of PGF are inappropriately low in maternal blood both before and during a PE gestation. Fetal concentrations of PGF appear to mirror maternal circulating concentrations. Using Pgf-/- mice that may model effects of PE on offspring, we demonstrated altered central nervous system vascularization, neuroanatomy, and behavior. Overall, we propose that development of the fetal brain is impaired in PE, making the offspring of preeclamptic pregnancies a unique cohort with greater risk of altered cognition and cerebrovasculature. These individuals may benefit from early interventions, either pharmacological or environmental. The early neonatal period may be a promising window for intervention while the developing brain retains plasticity.
Collapse
Affiliation(s)
- Vanessa R Kay
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - Matthew T Rätsep
- Department of Medicine, Queen's University, Kingston, Ontario, Canada
| | | | - B Anne Croy
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
2
|
Remaschi G, Ricci S, Cortimiglia M, De Vitis E, Iannuzzi L, Boni L, Azzari C, Dani C. TREC and KREC in very preterm infants: reference values and effects of maternal and neonatal factors. J Matern Fetal Neonatal Med 2019; 34:3946-3951. [PMID: 31885296 DOI: 10.1080/14767058.2019.1702951] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Objective: T-cell receptor excision circles (TREC) and kappa-deleting recombination excision circles (KREC) assays have been used for severe combined immunodeficiencies newborn screening (NBS). We assessed TREC and KREC NBS values in preterm infants and investigated if perinatal characteristics affect their values.Methods: We performed a retrospective study collecting data from TREC and KREC NBS database and from mothers' and infants' medical charts.Results: TREC and KREC values were lower in preterm infants born at 23-31 or 32-36 weeks of gestation than in term infants. Gestational age <28 weeks of gestation, leukopenia, and hypertensive disorders of pregnancy lowered TREC. Hypertensive disorders of pregnancy lowered KREC and intrapartum fever >38 °C increased it. Low TREC and KREC values were not associated to the risk of developing early-onset sepsis and late-onset sepsis.Conclusion: TREC and KREC levels are lower in preterm than term infants, but this did not increase the risk of neonatal sepsis.
Collapse
Affiliation(s)
- Giulia Remaschi
- Division of Neonatology, Careggi University Hospital of Florence, Florence, Italy
| | - Silvia Ricci
- Division of Pediatric Immunology, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy.,Department of Health Sciences, Meyer University Hospital, University of Florence, Florence, Italy
| | - Martina Cortimiglia
- Division of Pediatric Immunology, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy
| | - Elisa De Vitis
- Division of Pediatric Immunology, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy
| | - Laura Iannuzzi
- Margherita Birth Center, Careggi University Hospital of Florence, Florence, Italy
| | - Luca Boni
- Clinical Trials Coordinating Center, Careggi University Teaching Hospital of Florence, Florence, Italy
| | - Chiara Azzari
- Division of Pediatric Immunology, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy.,Department of Health Sciences, Meyer University Hospital, University of Florence, Florence, Italy
| | - Carlo Dani
- Division of Neonatology, Careggi University Hospital of Florence, Florence, Italy.,Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Italy Florence
| |
Collapse
|